Article Text


Blood glucose: of emerging importance in COPD exacerbations
  1. Emma H Baker1,
  2. Derek Bell2
  1. 1
    St George’s, University of London, London, UK
  2. 2
    Imperial College, Chelsea and Westminster Hospital, London, UK
  1. Correspondence to Dr Emma Baker, Centre for Clinical Pharmacology, Division of Basic Medical Sciences, St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK; ebaker{at}

Statistics from

Elevated blood glucose is a well recognised and common pathophysiological response to acute illness. The underlying mechanisms include acute increases in hepatic glucose production and peripheral insulin resistance, driven by increases in glucocorticoids, catecholamines and proinflammatory cytokines.1 Acute hyperglycaemia can occur in any acutely unwell patient, irrespective of baseline glucose tolerance, if the illness is sufficiently severe. Acute hyperglycaemia is associated with poor outcomes from a wide range of acute illnesses including myocardial infarction,2 stroke,3 trauma4 and pneumonia.5

The data in relation to hyperglycaemia and acute exacerbations of chronic obstructive pulmonary disease (COPD) are now beginning to emerge. In a previous study, more than 50% patients with acute exacerbations of COPD had random blood glucose ⩾7 mM during their hospital stay.6 This retrospective study could not fully elucidate the relative contributions of acute illness, steroid therapy and underlying diabetes to development of hyperglycaemia. Nevertheless blood glucose ⩾7 mM was significantly associated with increased risk of death or prolonged hospital stay, and the absolute risk of this composite adverse outcome increased by 15% for each 1 mM increase in blood glucose.

It is also known that acute hypercapnic respiratory failure is an independent predictor of poor outcome for patients with COPD exacerbations. Non-invasive ventilation (NIV) reduces the likelihood of endotracheal intubation, treatment failure and mortality.7 Moretti and colleagues found that “metabolic complications” of COPD exacerbations, including hyperglycaemia defined as blood glucose >11 mM, were independently associated with “late failure” (>48 h) of NIV after initial success.8 In this study only ∼7% patients had blood glucose >11 mM and the relationship between more moderate hyperglycaemia (>6–11 mM) and outcomes was not determined. Interestingly all of the patients with late NIV failure who had admission blood glucose >11 mM subsequently developed pulmonary infection, which may have contributed to NIV failure or death.

The study by Chakrabarti and colleagues in this issue of Thorax (see page 857) investigated the relationship between hyperglycaemia and NIV outcome prospectively in unselected COPD patients with acute hypercapnic respiratory failure.9 They found that hyperglycaemia, defined as random blood glucose ⩾7 mM within 24 h of hospital admission, was present in 50% patients, consistent with previous findings.6 NIV failure was significantly more common in patients with (34%) than without (2%) hyperglycaemia, and blood glucose was higher in those in whom NIV failed (mean (SD) 9.0 (3.2) mM) than those in whom NIV was successful (7.0 (2.2) mM). This reinforces the concept that even moderate hyperglycaemia may be associated with poorer prognosis in acute illness.

It is not known whether hyperglycaemia is a direct cause of poor outcomes from COPD exacerbations or acts as a marker for other adverse prognostic factors such as treatment variation, comorbidity or severity of acute illness. In their prospective study, Chakrabarti and colleagues provide some new insights into the underlying mechanisms. They found that the association between hyperglycaemia and NIV failure in COPD exacerbations was not explained either by oral corticosteroid use immediately before admission or by underlying diabetes mellitus. Although animal studies have shown that respiratory acidosis causes glucose intolerance by inducing hepatic and peripheral insulin resistance,10 in this study hyperglycaemia predicted NIV outcomes independently of pH and was not merely a marker for low pH. The effect of hyperglycaemia was also independent of APACHE II (Acute Physiology and Chronic Health Evaluation II) score, a marker of illness severity.

Limitations of the study by Chakrabarti et al include small sample size and lack of information relevant to underlying glucose intolerance such as body mass index and previous episodes of hyperglycaemia during exacerbations. As they point out, glucose was only recorded once on admission and no attempt was made to quantify hyperglycaemia after admission or relate this to outcomes. The authors also do not describe the causes of NIV failure or death in their patients and so have missed an opportunity to explore a causative role for hyperglycaemia in NIV failure. Potential detrimental effects of hyperglycaemia include augmentation of inflammation and infection, and insulin resistance could increase muscle catabolism. Experimental hyperglycaemia induced an acute rise in interleukin-6 (IL-6), tumour necrosis factor α (TNFα) and IL-18 that was inhibited by glutathione, indicating induction of proinflammatory cytokines via an oxidative mechanism.11 C-reactive protein was elevated in people with impaired glucose tolerance compared with those with normal glucose tolerance.12 13 In two separate studies of COPD exacerbations, acute hyperglycaemia and underlying diabetes were associated with increased isolation of multiple pathogens and Staphylococcus aureus6 and Gram-negative bacteria14 from sputum. Hyperglycaemia is associated with elevated glucose concentrations in tissues and bronchial aspirates15 where it may stimulate infection by enhancing bacterial growth16 and by promoting bacterial interaction with the airway epithelium.17 Hyperglycaemia also impairs both innate and adaptive immunity, suppressing the host response to infection. Skeletal muscle abnormalities are common in patients with COPD, and exacerbations requiring hospitalisation are associated with increasing muscle weakness18 and reduction in lean body mass.19 As insulin is an anabolic hormone, insulin resistance could exacerbate muscle loss during a COPD exacerbation. In support of this, patients with critical illness who did not receive insulin therapy had lower skeletal muscle total protein concentrations than those receiving pharmacological doses of insulin.20

The association between hyperglycaemia and poor outcomes raises the important question as to whether correction of hyperglycaemia with insulin could improve outcomes from COPD exacerbations. Initial enthusiasm for tight glycaemic control in critical illness was generated by a single-centre, randomised controlled trial (RCT) of intensive insulin therapy compared with usual treatment in cardiothoracic patients requiring a stay in an Intensive Care Unit (ICU).21 Tight glycaemic control (blood glucose 4.4–6.1 mM) reduced mortality by 42% compared with conventional glycaemic control (blood glucose 10–11.1 mM). In a second RCT by the same investigators in medical ICU patients, tight glycaemic control did not reduce mortality in the whole group but did reduce in-hospital mortality in those requiring a stay in the ICU for ⩾3 days.22 However, patients receiving tight glycaemic control had accelerated weaning from mechanical ventilation and accelerated discharge. Subsequently tight glycaemic control was shown significantly to accelerate resolution of infection21 and inflammation,23 to prevent nosocomial infection24 and to reduce catabolism.25 26

Benefits of tight glycaemic control for critical illness have become less clear with the recent publication of NICE-SUGAR.27 This large RCT, performed in adults expected to require ICU treatment for ⩾3 days, found that intensive blood glucose control (4.5–6.0 mM) increased mortality (odds ratio 1.14, 95% CI 1.02 to 1.28) compared with conventional glucose control (⩽10 mM). A meta-analysis of 26 studies including these three large RCTs found no difference in mortality with tight or conventional glycaemic control.28 Tight glycaemic control was associated with a sixfold increased risk of hypoglycaemia which may have offset beneficial effects of glycaemic control and insulin therapy. The optimal strategy for management of hyperglycaemia in ICU patients is now unclear, and more moderate glycaemic control (blood glucose 8–10 mM) is currently recommended.29

Despite recent ICU findings, there remains a potential case for testing glycaemic control in patients with COPD with exacerbations requiring hospitalisation. Oral corticosteroids are a key component of exacerbation management in COPD, and subgroup analysis of NICE-SUGAR suggests heterogeneity of response to glycaemic control in those receiving steroids.29 Infection, inflammation and muscle weakness are prominent components of COPD exacerbations and all are improved by glycaemic control with insulin. Most patients with COPD exacerbations, even those requiring NIV, are less critically unwell than those in ICU studies and may be more resistant to the detrimental effects of hypoglycaemia. Tight glycaemic control can be implemented in the acute medical unit outside the intensive care setting with similar efficacy and risks of hypoglycaemia as those seen in ICU studies.30 However, optimal glycaemic control in COPD remains unclear and ICU studies have shown us that intensive strategies should not be adopted without rigorous testing in multicentre clinical trials.

In their paper, Chakrabarti and colleagues wisely steer clear of discussing the sticky issue of glycaemic control during COPD exacerbations. Rather they concentrate on the interesting finding that blood glucose <7 mM in combination with respiratory rate <30/min predicted a successful outcome from NIV in 97% of patients with acute hypercapnic respiratory failure. Treatment failure was more likely (but not inevitable) in those with respiratory rate >30/min and hyperglycaemia. If their findings are confirmed in other patient cohorts, this simple prognostic index could support discussions with COPD patients and their families prior to initiation of NIV and allow targeting of more intensive monitoring and treatment for those at greater risk of NIV failure. However, measurement of blood glucose is not currently part of NICE/BTS (National Institute for Health and Clinical Excellence/British Thoracic Society) guidelines for the management of COPD exacerbations,31 and data about blood glucose were not collected in the 2008 national COPD audit. This paper adds to the growing evidence that hyperglycaemia is important during COPD exacerbations and supports inclusion of blood glucose assessment in future recommendations. However, it does not clarify underlying mechanisms or make the case for tight glycaemic control, both of which require further study.


View Abstract


  • Competing interests None.

  • Provenance and Peer review Commissioned; not externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles